Tuesday, January 11, 2022 8:36:38 AM
Many thanks to Dr. Missling for the A3-71 P1 data results. I look forward to the imminent Avatar data.
Also, for making the effort to organize subject verb agreement which makes it easier for English speaking people to understand and relax while listening. It is appreciated.
When we look at the safety P-1 data between the two compounds A-371 looks, from the profile extremely well tolerated, so we had much broader therapeutic dose range.
We dosed in Anavex2-73 up to 60 mg in the phase one and in Anavex3-71 we dosed up to 200mg so it’s a broader range in Anavex3-71.
Dr. Missling said there were factors that could not be anticipated that delayed the data releases such as;
Flights have been delayed, communication was impacted, sampling, shipments and so forth but he believes everything is on track and especially on Avatar is coming around soon.
With Orphan Drug Designation in FTD we’re planning a quasi Basket Trial where we put 3 indications in one study and we see how the drug effect is working on the longitudinal side and compared to placebo. So it will be a placebo controlled study where we look at all three indications at the same time.
The protocol will likely include separately, patients with Alzheimer’s disease, Alzheimer’s pathology, patients with Schizophrenia and Frontal Temporal Dementia. Among them we will make sure we will capture what is considered state of art; Patients who are declining, patients who are homogenous in the pathology which is why we stated it will be a biomarker driven inclusion criteria as well as in the outcome study.
Biomarkers;
A3-71 and A2-73 are both sigma one agonist receptors.
Both have agonistic affinity with the M-1 muscarinic receptor, known to be CNS beneficial activators.
A2-73 has stronger antagonistic affinity on the M-2 receptor.
A3-71 has a higher affinity to the S1 in vitro than 2-73. We don’t know yet if that translates into higher biological activity. Affinity level does not always translate to a higher activity.
A3-71 was good at removing Tau pathology which is what FTD is considered to be.
A3-71 is very good at reducing abeta and inflammation in a triple transgenic animal model.
Could also go into the clinic with depression and other rare diseases later.
Planning on doing a study with eeg/erp, the Consortium is currently exploring these as surrogate biomarkers.
As well as blood and CSF biomarkers.
Looking at neuro-filament light change, NFL. Plasma and serum concentration, glutamate and other related… my recording dropped out here for a few seconds.
Biomarkers may show earlier separation in FTD and Alzheimer’s studies. Hoping to have cohort data on 3-71 in 2nd half of this year IF everything goes smoothly.
3-71 has a broad therapeutic window from 5mg to about 160mg, which is broader than 2-73 where dosing was up to 60mg in the P-1.
Dosing higher doesn’t necessarily mean better, however.
Anavex 3-71 is very well tolerated.
Recent AVXL News
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM